Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Godela M. Brosnahan

TitleAffiliate
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone303/724-1687

    Collapse Research 
    Collapse research activities and funding
    R21DK107969     (BROSNAHAN, GODELA M)Aug 20, 2016 - Jul 31, 2019
    NIH
    Feasibility study of metformin therapy in ADPKD
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Bae KT, Tao C, Feldman R, Yu ASL, Torres VE, Perrone RD, Chapman AB, Brosnahan G, Steinman TI, Braun WE, Mrug M, Bennett WM, Harris PC, Srivastava A, Landsittel DP, Abebe KZ. Volume Progression and Imaging Classification of Polycystic Liver in Early Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2022 03; 17(3):374-384. PMID: 35217526.
      View in: PubMed
    2. Steele C, You Z, Gitomer BY, Brosnahan GM, Abebe KZ, Braun WE, Chapman AB, Harris PC, Perrone RD, Steinman TI, Torres VE, Yu ASL, Chonchol M, Nowak KL. PKD1 Compared With PKD2 Genotype and Cardiac Hospitalizations in the Halt Progression of Polycystic Kidney Disease Studies. Kidney Int Rep. 2022 Jan; 7(1):117-120. PMID: 35005320.
      View in: PubMed
    3. Brosnahan GM, Wang W, Gitomer B, Struemph T, George D, You Z, Nowak KL, Klawitter J, Chonchol MB. Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study. Am J Kidney Dis. 2022 04; 79(4):518-526. PMID: 34391872.
      View in: PubMed
    4. Nowak KL, Murray K, You Z, Gitomer B, Brosnahan G, Abebe KZ, Braun W, Chapman A, Harris PC, Miskulin D, Perrone R, Torres V, Steinman T, Yu A, Chonchol M. Pain and Obesity in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis of the Halt Progression of Polycystic Kidney Disease (HALT-PKD) Studies. Kidney Med. 2021 Jul-Aug; 3(4):536-545.e1. PMID: 34401721.
      View in: PubMed
    5. Brosnahan GM, You Z, Wang W, Gitomer BY, Chonchol M. Serum Uric Acid and Progression of Autosomal Dominant Polycystic Kidney Disease: Results from the HALT PKD Trials. Curr Hypertens Rev. 2021; 17(3):228-237. PMID: 32807060.
      View in: PubMed
    6. Lavu S, Vaughan LE, Senum SR, Kline TL, Chapman AB, Perrone RD, Mrug M, Braun WE, Steinman TI, Rahbari-Oskoui FF, Brosnahan GM, Bae KT, Landsittel D, Chebib FT, Yu AS, Torres VE, Harris PC. The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD. JCI Insight. 2020 08 06; 5(15). PMID: 32634120.
      View in: PubMed
    7. Grau L, Gitomer B, McNair B, Wolf M, Harris P, Brosnahan G, Torres V, Steinman T, Yu A, Chapman A, Chonchol M, Nowak KL. Interactions between FGF23 and Genotype in Autosomal Dominant Polycystic Kidney Disease. Kidney360. 2020 Jul; 1(7):648-656. PMID: 33305291.
      View in: PubMed
    8. Bae KT, Shi T, Tao C, Yu ASL, Torres VE, Perrone RD, Chapman AB, Brosnahan G, Steinman TI, Braun WE, Srivastava A, Irazabal MV, Abebe KZ, Harris PC, Landsittel DP. Expanded Imaging Classification of Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2020 07; 31(7):1640-1651. PMID: 32487558.
      View in: PubMed
    9. Brosnahan G. Quest for the Cure: Testing the Old and New to Prevent Progression of Autosomal Dominant Polycystic Kidney Disease. Kidney Med. 2019 Nov-Dec; 1(6):329-331. PMID: 33015606.
      View in: PubMed
    10. Hanudel MR, Salusky IB, Pereira RC, Wang W, You Z, Nowak KL, Brosnahan GM, Torres VE, Chapman AB, Perrone RD, Steinman TI, Bae KT, Gitomer BY, Chonchol MB. Erythropoietin and Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease Patients. Kidney Int Rep. 2019 Dec; 4(12):1742-1748. PMID: 31844811.
      View in: PubMed
    11. Brosnahan GM, Moore CG, Abebe KZ. In Reply to 'Artificial Intelligence Can Predict GFR Decline During the Course of ADPKD' and 'Linear and Nonlinear Estimated GFR Slopes in ADPKD Patients Reaching ESRD'. Am J Kidney Dis. 2018 06; 71(6):913. PMID: 29609976.
      View in: PubMed
    12. Dad T, Abebe KZ, Bae KT, Comer D, Torres VE, Czarnecki PG, Schrier RW, Steinman TI, Moore CG, Chapman AB, Kaya D, Tao C, Braun WE, Winklhofer FT, Brosnahan G, Hogan MC, Miskulin DC, Rahbari Oskoui F, Flessner MF, Perrone RD. Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease. Kidney Int Rep. 2018 May; 3(3):619-624. PMID: 29854969.
      View in: PubMed
    13. Brosnahan GM, Abebe KZ, Moore CG, Rahbari-Oskoui FF, Bae KT, Grantham JJ, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Hogan MC, Perrone RD, Miskulin DC, Steinman TI, Torres VE. Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials. Am J Kidney Dis. 2018 05; 71(5):666-676. PMID: 29306517.
      View in: PubMed
    14. Brosnahan GM, Abebe KZ, Moore CG, Bae KT, Braun WE, Chapman AB, Flessner MF, Harris PC, Hogan MC, Perrone RD, Rahbari-Oskoui FF, Steinman TI, Torres VE. Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade? Curr Hypertens Rev. 2018; 14(1):39-47. PMID: 29564978.
      View in: PubMed
    15. Braun WE, Abebe KZ, Brosnahan G, Patterson CG, Chapman AB, Harris PC, Hogan MC, Perrone RD, Torres VE, Miskulin DC, Steinman TI, Winklhofer FT, Rahbari-Oskoui FF, Czarnecki PG, Bae KT, Grantham JJ, Flessner MF, Schrier RW. ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing. Am J Kidney Dis. 2018 02; 71(2):294-296. PMID: 29203126.
      View in: PubMed
    16. Nowak KL, You Z, Gitomer B, Brosnahan G, Torres VE, Chapman AB, Perrone RD, Steinman TI, Abebe KZ, Rahbari-Oskoui FF, Yu ASL, Harris PC, Bae KT, Hogan M, Miskulin D, Chonchol M. Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2018 02; 29(2):571-578. PMID: 29118087.
      View in: PubMed
    17. Brosnahan GM, Abebe KZ, Rahbari-Oskoui FF, Patterson CG, Bae KT, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Perrone RD, Steinman TI, Torres VE. Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials. Curr Hypertens Rev. 2017; 13(2):109-120. PMID: 28460625.
      View in: PubMed
    18. Torres VE, Abebe KZ, Schrier RW, Perrone RD, Chapman AB, Yu AS, Braun WE, Steinman TI, Brosnahan G, Hogan MC, Rahbari FF, Grantham JJ, Bae KT, Moore CG, Flessner MF. Dietary salt restriction is beneficial to the management of autosomal dominant polycystic?kidney disease. Kidney Int. 2017 02; 91(2):493-500. PMID: 27993381.
      View in: PubMed
    19. Heyer CM, Sundsbak JL, Abebe KZ, Chapman AB, Torres VE, Grantham JJ, Bae KT, Schrier RW, Perrone RD, Braun WE, Steinman TI, Mrug M, Yu AS, Brosnahan G, Hopp K, Irazabal MV, Bennett WM, Flessner MF, Moore CG, Landsittel D, Harris PC. Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2016 09; 27(9):2872-84. PMID: 26823553.
      View in: PubMed
    20. Moore CG, Spillane S, Simon G, Maxwell B, Rahbari-Oskoui FF, Braun WE, Chapman AB, Schrier RW, Torres VE, Perrone RD, Steinman TI, Brosnahan G, Czarnecki PG, Harris PC, Miskulin DC, Flessner MF, Bae KT, Abebe KZ, Hogan MC. Closeout of the HALT-PKD trials. Contemp Clin Trials. 2015 Sep; 44:48-55. PMID: 26231556.
      View in: PubMed
    21. Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Moore CG, Perrone RD. Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med. 2014 Dec 11; 371(24):2267-76. PMID: 25399731.
      View in: PubMed
    22. Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG, Chapman AB. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014 Dec 11; 371(24):2255-66. PMID: 25399733.
      View in: PubMed
    23. Klawitter J, Reed-Gitomer BY, McFann K, Pennington A, Klawitter J, Abebe KZ, Klepacki J, Cadnapaphornchai MA, Brosnahan G, Chonchol M, Christians U, Schrier RW. Endothelial dysfunction and oxidative stress in polycystic kidney disease. Am J Physiol Renal Physiol. 2014 Dec 01; 307(11):F1198-206. PMID: 25234311.
      View in: PubMed
    24. Hogan MC, Abebe K, Torres VE, Chapman AB, Bae KT, Tao C, Sun H, Perrone RD, Steinman TI, Braun W, Winklhofer FT, Miskulin DC, Rahbari-Oskoui F, Brosnahan G, Masoumi A, Karpov IO, Spillane S, Flessner M, Moore CG, Schrier RW. Liver involvement in early autosomal-dominant polycystic kidney disease. Clin Gastroenterol Hepatol. 2015 Jan; 13(1):155-64.e6. PMID: 25111236.
      View in: PubMed
    25. Schrier RW, Brosnahan G, Cadnapaphornchai MA, Chonchol M, Friend K, Gitomer B, Rossetti S. Predictors of autosomal dominant polycystic kidney disease progression. J Am Soc Nephrol. 2014 Nov; 25(11):2399-418. PMID: 24925719.
      View in: PubMed
    26. Brosnahan G. Treatment of hypertension in chronic kidney disease: does one size fit all? A narrative review from a nephrologist's perspective. Curr Hypertens Rev. 2014; 10(3):155-65. PMID: 25567505.
      View in: PubMed
    27. Klawitter J, Klawitter J, McFann K, Pennington AT, Abebe KZ, Brosnahan G, Cadnapaphornchai MA, Chonchol M, Gitomer B, Christians U, Schrier RW. Bioactive lipid mediators in polycystic kidney disease. J Lipid Res. 2014 06; 55(6):1139-49. PMID: 24343898.
      View in: PubMed
    28. Brosnahan G, Fraer M. Management of chronic kidney disease: what is the evidence? South Med J. 2010 Mar; 103(3):222-30. PMID: 20134375.
      View in: PubMed
    29. Brosnahan G, Fraer M. Chronic kidney disease: whom to screen and how to treat, part 1: definition, epidemiology, and laboratory testing. South Med J. 2010 Feb; 103(2):140-6. PMID: 20065899.
      View in: PubMed
    30. Banerjee S, Brosnahan G. Polymyalgia rheumatica in a renal transplant patient. J Ark Med Soc. 2008 Nov; 105(5):115-7. PMID: 19006913.
      View in: PubMed
    31. Brosnahan G, Gokden N, Swaminathan S. Acute interstitial nephritis due to deferasirox: a case report. Nephrol Dial Transplant. 2008 Oct; 23(10):3356-8. PMID: 18653899.
      View in: PubMed
    32. Barone GW, Wright CF, Krause MW, Brosnahan GM, Portilla D, Banerjee S, McCowan TC, Culp WC, Yousaf M. Hemodialysis access success: beyond the operating room. Am J Surg. 2007 Nov; 194(5):668-71. PMID: 17936432.
      View in: PubMed
    33. Brosnahan GM. Volume progression in polycystic kidney disease. N Engl J Med. 2006 Aug 17; 355(7):733; author reply 733-4. PMID: 16914712.
      View in: PubMed
    34. Schrier R, McFann K, Johnson A, Chapman A, Edelstein C, Brosnahan G, Ecder T, Tison L. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol. 2002 Jul; 13(7):1733-9. PMID: 12089368.
      View in: PubMed
    35. Persu A, Devuyst O, Lannoy N, Materne R, Brosnahan G, Gabow PA, Pirson Y, Verellen-Dumoulin C. CF gene and cystic fibrosis transmembrane conductance regulator expression in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2000 Dec; 11(12):2285-2296. PMID: 11095651.
      View in: PubMed
    36. Ecder T, Chapman AB, Brosnahan GM, Edelstein CL, Johnson AM, Schrier RW. Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2000 Mar; 35(3):427-32. PMID: 10692268.
      View in: PubMed
    37. Ecder T, Edelstein CL, Chapman AB, Johnson AM, Tison L, Gill EA, Brosnahan GM, Schrier RW. Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 1999 May; 14(5):1113-6. PMID: 10344347.
      View in: PubMed
    Brosnahan's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (135) concept(s)
    _
    Co-Authors Expand Description
    See all (7) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)